FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Dermorphin

Dermorph

Fat Loss & Body Composition

Dermorphin is a naturally occurring seven-amino acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from the skin secretions of South American tree frogs of the genus Phyllomedusa. It is approximately 30-40 times more potent than morphine as a mu-opioid receptor agonist and contains the unusual D-alanine residue at position 2, making it one of the first discovered naturally occurring D-amino acid-containing peptides. It has gained notoriety for its illegal use in horse racing as a performance enhancer and pain masking agent.

작용 메커니즘

Naturally occurring heptapeptide isolated from the skin of South American tree frogs (Phyllomedusa). Potent and selective mu-opioid receptor agonist — approximately 30-40 times more potent than morphine. Contains D-alanine, which is rare in natural peptides.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Not recommended for human research due to extreme potency and opioid receptor agonism. Primarily of academic interest. Studied in pharmacological research for understanding mu-opioid receptor selectivity.

연구 노트

Clinical Research Status

Dermorphin has not been developed for human clinical use and has no active clinical trials or regulatory filings for any therapeutic indication. Research has been confined to pharmacological characterization, opioid receptor binding studies, and development of detection methods for equine anti-doping enforcement. It serves primarily as a research tool for understanding mu-opioid receptor pharmacology and the evolution of bioactive peptides in amphibian defense secretions.

Key Published Findings

Binding studies demonstrate that dermorphin has exceptionally high selectivity and affinity for mu-opioid receptors (Ki approximately 0.2-1.6 nM), significantly exceeding morphine in both potency and selectivity. The D-alanine residue at position 2 confers resistance to aminopeptidase degradation, extending its biological half-life compared to L-amino acid-containing endogenous opioid peptides. Research on dermorphin and its analogs has contributed significantly to understanding structure-activity relationships at the mu-opioid receptor and has led to development of several research tools for opioid pharmacology.

Safety Profile

As an extremely potent mu-opioid agonist, dermorphin carries all the risks associated with opioid intoxication including respiratory depression, profound sedation, physical dependence, and potentially fatal overdose. No therapeutic index has been established for humans, and the steep dose-response curve of highly potent opioids makes accidental overdose a significant risk. The absence of human pharmacokinetic data means that dosing, onset, duration, and drug interactions are completely unknown in clinical contexts.

Comparison to Related Compounds

Dermorphin is significantly more potent than morphine (30-40x) and fentanyl-like in its receptor binding affinity, though it maintains high mu-selectivity unlike some synthetic opioids that have broader receptor profiles. Its natural analog deltorphin (from the same frog species) is similarly potent but selective for delta-opioid receptors rather than mu-receptors. Compared to endogenous opioid peptides (endorphins, enkephalins), dermorphin's D-amino acid content provides superior metabolic stability and greater pharmacological potency.

Community Observations

Dermorphin is primarily known in the public sphere through horse racing scandals, where it has been detected in post-race urine samples from winning horses in multiple US states including Louisiana, Oklahoma, and New Jersey. Its use in horse racing is considered animal abuse by regulatory bodies, as it masks pain and allows injured horses to race at risk of catastrophic breakdown. Human recreational use is extremely rare due to limited availability and the extreme danger posed by its potency, with the research community treating it primarily as a pharmacological tool rather than a potential therapeutic.

반감기

~2-3 hours

재조성

Sterile saline

보관

건조한 상태

Store at -20C.

재조성된 상태

Refrigerate 2-8C. Use within 7 days.

미국 법적 상태

Not scheduled but DEA analog act may apply

또는 알려진 이름으로

Dermorph

자주 묻는 질문

Dermorphin란 무엇인가요?

Dermorphin is a naturally occurring seven-amino acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from the skin secretions of South American tree frogs of the genus Phyllomedusa. It is approximately 30-40 times more potent than morphine as a mu-opioid receptor agonist and contains the unusual D-alanine residue at position 2, making it one of the first discovered naturally occurring D-amino acid-containing peptides. It has gained notoriety for its illegal use in horse racing as a performance enhancer and pain masking agent.

Dermorphin는 어떻게 작용하나요?

Naturally occurring heptapeptide isolated from the skin of South American tree frogs (Phyllomedusa). Potent and selective mu-opioid receptor agonist — approximately 30-40 times more potent than morphine. Contains D-alanine, which is rare in natural peptides.

Dermorphin의 미국 규제 현황은 어떤가요?

Not scheduled but DEA analog act may apply

Dermorphin의 반감기는 얼마인가요?

~2-3 hours

Dermorphin의 다른 이름은 무엇인가요?

Dermorph

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기